The US-based biotechnology company Inari has secured $124 million through a Series E financing round, bringing the company's total funding raised to $475 million. The equity raised is expected to be used to further advance Inari’s multiplex gene-edited seed technology and to support the expansion of the company’s product portfolio. In addition to the equity fundraise, Inari has also entered into a refinanced and upsized loan agreement with K2 HealthVentures, allowing Inari to access up to $60 million in debt capital.